Close Menu

NEW YORK – Interpace Diagnostics said after the close of the market on Wednesday that its third quarter revenues increased 33 percent year over year.

The Parsippany, New Jersey-based firm also announced that it has changed its name to Interpace Biosciences to better reflect its new business model combining esoteric molecular diagnostic testing with the new drug discovery and development services business it acquired from Cancer Genetics in July.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.